News Releases

Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from the INS-212 study

During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection

Study met primary endpoint of culture conversion (p < 0.0001)

On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month

Paolo Tombesi named as Chief Financial Officer